ADS051

Showing: 1 - 1 of 1 Articles

Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis

Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases …